帕立骨化醇治疗血液透析患者并发SHPT的效果观察

A clinical observational study of hemodialysis patients with SHPT treated with paricalcitol

目的观察帕立骨化醇治疗维持性血液透析并发继发性甲状旁腺功能亢进(SHPT)患者6个月的疗效。方法选取40例血液透析合并SHPT的患者,分成观察组和对照组,分别使用帕立骨化醇和骨化三醇治疗6个月,监测治疗前、治疗后血清全段甲状旁腺素(iPTH)、血钙、血磷水平。比较2组患者治疗6个月后iPTH、血钙、血磷变化情况。结果治疗6个月后,观察组iPTH水平较对照组下降,观察组血钙水平较对照组上升幅度小,观察组血磷水平较对照组下降。结论帕立骨化醇治疗6个月能显著降低血透并发SHPT患者的iPTH水平,治疗效果显著,且不会增加高钙、高磷血症风险,药物安全性好。

Objective To observe the effectiveness of paricalcitol in the 6-month treatment of maintenance hemodialysis patients with secondary hyperparathyroidism(SHPT).Methods Forty maintenance hemodialysis patients with SHPT were selected and divided into observation group and control group.They were treated with paricalcitol or calcitriol for 6 months,respectively.Serum levels of intact parathyroid hormone(iPTH),calcium and phosphorus were monitored before and after treatment.The changes of iPTH,calcium and phosphorus were compared between the two groups after 6 months of treatment.Results After 6 months of treatment,the level of iPTH in the observation group decreased significantly compared with the control group,the level of calcium in the observation group increased slightly compared with the control group,and the level of phosphorus in the observation group decreased significantly compared with the control group.Conclusions This observational study shows that paricalcitol can significantly reduce the iPTH level in hemodialysis patients with SHPT after treatment for 6 months,without increasing the risk of hypercalcemia and hyperphosphatemia.